Sumitomo Posts 7.3 Billion Yen Net Loss in H1 on Kynmobi Write-Down

Sumitomo Pharma suffered its bottom-line dipping into the red ink in the first half of FY2022 as it booked an impairment loss of 54.4 billion yen following the forecast review of Kynmobi (apomorphine), a Parkinson’s med floundering in the US...read more